NZ630914A - Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation - Google Patents

Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Info

Publication number
NZ630914A
NZ630914A NZ630914A NZ63091413A NZ630914A NZ 630914 A NZ630914 A NZ 630914A NZ 630914 A NZ630914 A NZ 630914A NZ 63091413 A NZ63091413 A NZ 63091413A NZ 630914 A NZ630914 A NZ 630914A
Authority
NZ
New Zealand
Prior art keywords
transplantation
methods
seq
treating diabetes
pancreatic islets
Prior art date
Application number
NZ630914A
Other languages
English (en)
Inventor
Giovanni Monteleone
Peter Buchwald
Luca Inverardi
Antonello Pileggi
Camillo Ricordi
Alice Tomei
Original Assignee
Nogra Pharma Ltd
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd, Univ Miami filed Critical Nogra Pharma Ltd
Publication of NZ630914A publication Critical patent/NZ630914A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ630914A 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation NZ630914A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625904P 2012-04-18 2012-04-18
PCT/US2013/037150 WO2013158868A1 (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Publications (1)

Publication Number Publication Date
NZ630914A true NZ630914A (en) 2017-01-27

Family

ID=48326412

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630914A NZ630914A (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Country Status (14)

Country Link
US (3) US10081809B2 (enExample)
EP (1) EP2839004B1 (enExample)
JP (2) JP6348484B2 (enExample)
KR (1) KR20150003824A (enExample)
CN (2) CN104487574B (enExample)
AU (1) AU2013249191B2 (enExample)
CA (1) CA2870547A1 (enExample)
DK (1) DK2839004T3 (enExample)
ES (1) ES2732252T3 (enExample)
IN (1) IN2014DN08158A (enExample)
MX (1) MX370149B (enExample)
NZ (1) NZ630914A (enExample)
RU (1) RU2667960C2 (enExample)
WO (1) WO2013158868A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
JP5719776B2 (ja) 2008-11-13 2015-05-20 ノグラ ファーマ リミテッド アンチセンス組成物およびその作製および使用
WO2013037970A1 (en) 2011-09-15 2013-03-21 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
NZ630914A (en) 2012-04-18 2017-01-27 Nogra Pharma Ltd Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
EP2940115B1 (en) * 2014-04-30 2018-10-17 The Procter and Gamble Company Cleaning composition
KR20170005058A (ko) 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
ES2718380T3 (es) * 2015-10-29 2019-07-01 Procter & Gamble Composición detergente líquida
EP3162878A1 (en) * 2015-10-29 2017-05-03 The Procter and Gamble Company Liquid detergent composition
JP2019505598A (ja) 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法
CN112840025A (zh) * 2018-05-08 2021-05-25 迈阿密大学 用于将治疗性核酸递送到组织的材料方法
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
EP1456380B1 (en) * 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
GB2417727B (en) 2003-06-13 2008-01-16 Alnylam Europe Ag Double-stranded ribonucleic acid with increased effectiveness in an organism
ITRM20030393A1 (it) * 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
CA2580126C (en) 2004-09-28 2014-08-26 Quark Biotech, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
RU2434942C2 (ru) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний
WO2007039151A1 (en) * 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
CA2720675C (en) * 2008-04-18 2019-08-27 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
JP5719776B2 (ja) 2008-11-13 2015-05-20 ノグラ ファーマ リミテッド アンチセンス組成物およびその作製および使用
WO2013037970A1 (en) 2011-09-15 2013-03-21 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
NZ630914A (en) 2012-04-18 2017-01-27 Nogra Pharma Ltd Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
JP6502863B2 (ja) 2013-03-15 2019-04-17 ノグラ ファーマ リミテッド 結腸直腸癌を処置する方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
KR20170005058A (ko) 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
US20170233736A1 (en) 2014-10-17 2017-08-17 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
EP3355896A2 (en) 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
WO2017144689A1 (en) 2016-02-24 2017-08-31 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
WO2018122376A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
KR20150003824A (ko) 2015-01-09
US20150315573A1 (en) 2015-11-05
JP2015514778A (ja) 2015-05-21
EP2839004A1 (en) 2015-02-25
AU2013249191B2 (en) 2019-01-03
MX370149B (es) 2019-12-03
US10443056B2 (en) 2019-10-15
CN104487574A (zh) 2015-04-01
DK2839004T3 (da) 2019-07-01
WO2013158868A1 (en) 2013-10-24
JP6348484B2 (ja) 2018-06-27
JP2018131468A (ja) 2018-08-23
CN107252492A (zh) 2017-10-17
HK1207117A1 (en) 2016-01-22
US10081809B2 (en) 2018-09-25
RU2667960C2 (ru) 2018-09-25
EP2839004B1 (en) 2019-06-12
US20190136237A1 (en) 2019-05-09
CN104487574B (zh) 2017-07-07
MX2014012650A (es) 2015-04-08
AU2013249191A1 (en) 2014-10-09
RU2014146170A (ru) 2016-06-10
CA2870547A1 (en) 2013-10-24
US20200239884A1 (en) 2020-07-30
IN2014DN08158A (enExample) 2015-05-01
ES2732252T3 (es) 2019-11-21

Similar Documents

Publication Publication Date Title
NZ630914A (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
NZ603901A (en) Vectors and sequences for the treatment of diseases
PH12018500719A1 (en) Oligonucleotide compositions and methods thereof
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
MX2011013176A (es) Motivos de modificación química para inhibidores y miméticos del miarn.
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
NZ630596A (en) Methods for treatment of alport syndrome
NZ631512A (en) Compositions and methods for modulating apolipoprotein (a) expression
IN2014DN10390A (enExample)
HK1203513A1 (en) Methods of preparing substituted nucleotide analogs
MX2011008383A (es) Agonistas basados en acido ribonucleico sintetico de receptor 7 tipo toll.
HK1203552A1 (en) Differentiation of human embryonic stem cells into single hormonal insulin positive cells
TN2015000079A1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
MX2021014206A (es) Oligonucleotidos gapmer modificados y metodos de uso.
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
EP3301112A3 (en) Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids
MX2013005875A (es) Inhibidores de microarn que comprenden nucleotidos bloqueados.
PH12013502402A1 (en) Method for treating non-small cell lung cancer
EP4335502A3 (en) Modified u6 promoter system for tissue specific expression
JP2015514778A5 (enExample)
IN2014DN10899A (enExample)
MA39990A (fr) Induction de régénération cardiaque par micro-arn
WO2013067531A3 (en) Methods of using microrna 195 in providing neuroprotection
NZ741841A (en) Antisense oligonucleotides for use in treating alzheimer’s disease
MX348555B (es) Agente preventivo o terapeutico contra la fibrosis.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20170818

LAPS Patent lapsed